Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butyric Acid SCHEMBL4162510 | 0.90 | PKM (0.37) | PKMGAAKDM4EPARP1BRD4 | |
| Butyric Acid SCHEMBL4171971 | 0.89 | PKM (0.36) | PKMGAAKDM4EALDH1A1L3MBTL1 | |
| Butyric Acid SCHEMBL4161012 | 0.89 | ALDH1A1 (0.36) | GRIN1KDM4EALDH1A1L3MBTL1BRD4 | |
| Butyric Acid SCHEMBL4166911 | 0.85 | RXFP1 (0.43) | PKMGAAHTR2AHTR2CKDM4E | |
| Butyric Acid SCHEMBL4159473 | 0.80 | RXFP1 (0.40) | GAAKDM4EALDH1A1L3MBTL1 | |
| Butyric Acid SCHEMBL4155204 | 0.80 | RXFP1 (0.40) | GAAKDM4EALDH1A1L3MBTL1BRD4 | |
| Butyric Acid SCHEMBL4157862 | 0.80 | RXFP1 (0.40) | GAAKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL4171744 | 0.79 | PKM (0.35) | PKMGAAGRIN1 | |
| Butyric Acid SCHEMBL4161192 | 0.79 | ROCK2 (0.33) | ROCK2 | |
| Butyric Acid SCHEMBL4169377 | 0.78 | KDM4E (0.34) | GAAGRIN1KDM4EALDH1A1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | MAP3K1, MAP3K2, MAP3K7 | PKM 276/4885GAA 3035/4885GRIN1 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.